Andrew Park, Dustin Anderson, Ricardo A Battaglino, Nguyen Nguyen, Leslie R Morse
{"title":"Ibuprofen use is associated with reduced C-reactive protein and interleukin-6 levels in chronic spinal cord injury.","authors":"Andrew Park, Dustin Anderson, Ricardo A Battaglino, Nguyen Nguyen, Leslie R Morse","doi":"10.1080/10790268.2020.1773029","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To assess the association between ibuprofen use and the systemic inflammatory biomarkers C-reactive protein (CRP) and interleukin-6 (IL-6) in chronic Spinal Cord Injury (SCI).<b>Study design:</b> Prospective cohort study.<b>Setting:</b> Community dwelling individuals with SCI.<b>Participants:</b> 338 (278 male, 60 female) community dwelling individuals with chronic SCI (≥1-year post-injury).<b>Interventions:</b> None.<b>Main outcome measures:</b> CRP and IL-6 levels were quantified by ultra-sensitive ELISA assay. General linear models were used to assess associations between various clinical and demographic factors and CRP and IL-6 levels.<b>Results:</b> There were 50 active ibuprofen users and 288 non-users. After adjusting for clinical and demographic factors, ibuprofen users had significantly lower CRP levels (2.3 mg/L versus 3.5 mg/L, P = 0.04) and IL-6 levels (3.2 pg/ml versus 4.0 pg/ml, P = 0.04) compared to nonusers.<b>Conclusions:</b> Our study suggests that self-reported ibuprofen use may be negatively associated with CRP and IL-6 levels in chronic SCI after adjusting for known confounding factors, and suggests ibuprofen use may be an important, potential variable to consider in future studies focused on systemic inflammation in SCI. Future prospective studies require assessing frequency, duration, and dosage-dependent effects of ibuprofen on systemic markers of inflammation in chronic SCI. These findings may support future clinical trials to determine safety and efficacy of ibuprofen treatment for various outcomes in chronic SCI.</p>","PeriodicalId":501560,"journal":{"name":"The Journal of Spinal Cord Medicine","volume":" ","pages":"117-125"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/10790268.2020.1773029","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Spinal Cord Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10790268.2020.1773029","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/6/4 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 12
Abstract
Objective: To assess the association between ibuprofen use and the systemic inflammatory biomarkers C-reactive protein (CRP) and interleukin-6 (IL-6) in chronic Spinal Cord Injury (SCI).Study design: Prospective cohort study.Setting: Community dwelling individuals with SCI.Participants: 338 (278 male, 60 female) community dwelling individuals with chronic SCI (≥1-year post-injury).Interventions: None.Main outcome measures: CRP and IL-6 levels were quantified by ultra-sensitive ELISA assay. General linear models were used to assess associations between various clinical and demographic factors and CRP and IL-6 levels.Results: There were 50 active ibuprofen users and 288 non-users. After adjusting for clinical and demographic factors, ibuprofen users had significantly lower CRP levels (2.3 mg/L versus 3.5 mg/L, P = 0.04) and IL-6 levels (3.2 pg/ml versus 4.0 pg/ml, P = 0.04) compared to nonusers.Conclusions: Our study suggests that self-reported ibuprofen use may be negatively associated with CRP and IL-6 levels in chronic SCI after adjusting for known confounding factors, and suggests ibuprofen use may be an important, potential variable to consider in future studies focused on systemic inflammation in SCI. Future prospective studies require assessing frequency, duration, and dosage-dependent effects of ibuprofen on systemic markers of inflammation in chronic SCI. These findings may support future clinical trials to determine safety and efficacy of ibuprofen treatment for various outcomes in chronic SCI.
目的:探讨慢性脊髓损伤(SCI)患者布洛芬使用与全身炎症生物标志物c反应蛋白(CRP)和白细胞介素-6 (IL-6)的关系。研究设计:前瞻性队列研究。研究对象:社区居住的SCI患者。参与者:338名(278名男性,60名女性)慢性SCI(损伤后≥1年)社区居民。干预措施:没有。主要观察指标:超灵敏ELISA法测定CRP、IL-6水平。一般线性模型用于评估各种临床和人口学因素与CRP和IL-6水平之间的关系。结果:有活跃布洛芬使用者50人,非使用者288人。在调整了临床和人口统计学因素后,布洛芬使用者的CRP水平(2.3 mg/L vs 3.5 mg/L, P = 0.04)和IL-6水平(3.2 pg/ml vs 4.0 pg/ml, P = 0.04)明显低于非使用者。结论:我们的研究表明,在调整了已知的混杂因素后,慢性SCI患者自我报告的布洛芬使用情况可能与CRP和IL-6水平呈负相关,并且表明布洛芬的使用可能是一个重要的、潜在的变量,在未来专注于SCI全身性炎症的研究中需要考虑。未来的前瞻性研究需要评估布洛芬对慢性脊髓损伤全身炎症标志物的频率、持续时间和剂量依赖效应。这些发现可能支持未来的临床试验,以确定布洛芬治疗慢性脊髓损伤各种结局的安全性和有效性。